| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 15% YoY growth to ₹260.8 Cr; robust organic expansion. |
|---|---|
| Margins | Expansion to 18%+ EBITDA due to better product mix. |
| Demand visibility | Strong traction in critical care, fertility, and aesthetics segments. |
| Management confidence | High, focusing on Indore utilization and complex injectable leadership. |
Growth
Revenue grew 15% YoY to ₹260.8 Cr; EBITDA margins improved significantly to 18.09% from 14.6%.
Outlook
Management maintains 15-20% YoY revenue growth guidance with EBITDA margins expected to sustain at 18-20%.
Risks
High dependence on Indore plant utilization and EU certification timelines for export margin expansion.
Last quarter's promises, checked
Delivered
- Guided 30% Indore utilization by year-end → delivered 30% (= BEAT)
- Guided Indore EBITDA breakeven by Q4 → delivered Breakeven (= BEAT)
- Guided 15% YoY revenue growth → delivered 15% (= BEAT)
Partly delivered
- Guided 0.5-1% gross margin expansion → delivered 18.09% EBITDA margin (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹423.75
- Market cap
- ₹4,249 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 57.9×Sector 50.4×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Legal & Regulatory
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
- Value
- ₹0.02 Cr
Gufic BioSciences Credit Rating
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
- Value
- ₹516.0 Cr
Gufic BioSciences Annual General Meeting
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic BioSciences Management Change
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic BioSciences Investor Presentation: Key Takeaways
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.
Gufic BioSciences Q1 FY27 Results: Net Profit ₹22.3 Cr, Up 70.2% YoY
Gufic BioSciences Ltd reported revenue from operations of ₹260.8 Cr (+16.6% YoY) and net profit of ₹22.3 Cr (+70.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹22.3 Cr · +70.2% YoY